Abstract
Introduction Artemisinin-based combination therapies (ACTs) remain the WHO-recommended treatment for uncomplicated Plasmodium falciparum malaria. However, the emergence and spread of artemisinin resistance (ART-R) threatens ACT efficacy. ART-R is phenotypically expressed as delayed parasite clearance, which can facilitate ACT partner drug resistance. ART-R has been causally linked to specific mutations in the Pfkelch13 gene.
Methods and Analysis The systematic review and associated meta-analysis aim to determine the correlation between Pfkelch13 genotypes and clinical and parasitological response to ACTs from a globally representative dataset pooling individual patient data (IPD) from eligible published and unpublished studies. The eligibility criteria include Pfkelch13 genotyping results at baseline complemented by individually linked parasitological and clinical assessments following artemisinin-based treatment. The data will be curated, standardised, and analysed using this proposed statistical analysis plan, adhering to PRISMA-IPD guidelines. Our statistical analysis plan (SAP) will apply hierarchical modelling to assess the effect of Pfkelch13 mutations on parasite clearance half-life and therapeutic efficacy across different regions. This will include study sites as random effects in the model and potential predictors such as age, sex, baseline parasite load and other potential effect modifiers as fixed effects. This analysis will enhance the understanding of the influence of Pfkelch13 mutations on malaria treatment outcomes.
Ethics and Dissemination Data is obtained with informed consent and ethical approvals from the relevant countries and was pseudonymised before curation in the IDDO/WWARN repository. Data ownership remains with contributors. This IPD meta-analysis met the Oxford Tropical Research Ethics Committee criteria for waiving ethical review, as it is a secondary analysis of existing pseudonymised data. The resulting peer-reviewed publication will help strengthen and enhance the efficiency of ART-R surveillance and response and support policy decisions. The results will be submitted for publication in a peer-reviewed journal and shared at scientific conferences.
Registration details PROSPERO-registered (CRD42019133366)
Strengths and limitations of study
Inclusion of all available data based on a PROSPERO-registered systematic review of published and unpublished studies representing diverse patient and malaria parasite populations across varied global geographic regions, malaria transmission intensities and antimalarial drug pressures.
Individual patient data (IPD) meta-analysis is the only valid approach to determine the relationship between mutant alleles and parasite clearance, taking into account moderators of treatment response. This protocol outlines the combined efforts of stakeholders, national malaria programs, and researchers to investigate this relationship through data reuse.
This WWARN Data Management and Statistical Analysis Plan allows for standardised IPD to be included in the WWARN repository, which is then pooled into a single, quality-assured database using Clinical Data Interchange Standards Consortium (CDISC) standards.
IPD meta-analyses are limited by the data available, with inconsistencies in the type and completeness of covariates measured across the studies. For example, studies often only assess known mutations previously associated with ART-R, reducing the likelihood of detecting clinically relevant mutations not previously reported.
A key limitation is that current published studies may be insufficient to investigate the direct impact of Pfkelch13 mutant genotypes on the predictors/indicators of increased malaria transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Global Health EDCTP3 Joint Undertaking supports the MARC SE-Africa, and its members are established under the European Union's research and innovation programme, Horizon Europe (grant number and project number: 101103076). Grants from the ExxonMobil Foundation and the Bill & Melinda Gates Foundation funded this pooled analysis. Funders had not provided input on the study's planning, analysis, or presentation. Disclaimer: Views and opinions expressed are, however, those of the authors only and do not reflect those of the EU or the GH EDTP3 JU. Neither the EU nor GH EDCTP JU can be held responsible for them.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Data is obtained with informed consent and ethical approvals from the relevant countries and was pseudonymised before curation in the IDDO/WWARN repository. Data ownership remains with contributors. This IPD meta-analysis met the Oxford Tropical Research Ethics Committee criteria for waiving ethical review, as it is a secondary analysis of existing pseudonymised data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
List of abbreviations
- ACT
- Artemisinin-based Combination Therapies
- AL
- Artemether-Lumefantrine
- ART-R
- Artemisinin resistance
- CDISC
- Clinical Data Interchange Standards Consortium
- DRC
- Democratic Republic of the Congo
- EU GDPR
- European Union General Data Protection Regulation
- GRADE
- Grading of Recommendations Assessment, Development and Evaluation
- Hb
- Haemoglobin
- HL
- Parasite clearance half-life*
- IDDO
- Infectious Diseases Data Observatory
- IPD
- Individual Patient Data
- IPD-MA
- Individual Patient Data Meta-Analyses
- MARC SE-Africa
- Mitigating Antimalarial Resistance Consortium in South-East Africa
- PC½
- Parasite Clearance Half-life
- PCR
- Polymerase Chain Reaction
- PfKelch13
- Plasmodium falciparum Kelch 13
- PPP
- Proportion Parasite Positivity
- PRISMA-IPD
- Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data
- ROC
- Receiver Operating Characteristic
- RSA
- Ring-stage Survival Assay
- SAP
- Statistical Analysis Plan
- TES
- Therapeutic Efficacy Studies
- UK
- United Kingdom
- WCTL
- WWARN Clinical Trial Library
- WHO
- World Health Organization
- WWARN
- WorldWide Antimalarial Resistance Network
- WWARN DMSAP
- WWARN Clinical Module Data Management and Statistical Analytical Plan
- WWARN PCE
- WWARN Parasite Clearance Estimator
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos